NEW YORK (Reuters Health) – Vedolizumab does not appear to worsen COVID-19 outcomes in patients with inflammatory bowel disease (IBD), according to data from the
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
